Prilenia Therapeutics B.V.

Based in Israel, Prilenia Therapeutics B. V. is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). Prilenia Therapeutics B.

V. specializes in creating therapies for neurodegenerative diseases. Founded in 2018 in Herzliya, Israel, the company has engaged in 4 funding deals. Its latest funding round, Series B, garnered USD 10.

000 mn from investors including Amplitude, Forbion, and others, bringing the total amount raised to USD 10. 000 mn. The CEO is Limor Har, Michael MBChB. Prilenia Therapeutics is a clinical-stage biotechnology company primarily focused on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Huntington's disease and Amyotrophic Lateral Sclerosis (ALS).

Their flagship product, Pridopidine, is designed to address the underlying mechanisms of these conditions by modulating the activity of certain proteins involved in neuronal health. The company aims to enhance the quality of life for patients and their families affected by these debilitating diseases. Pridopidine has undergone various stages of clinical trials, with its most promising results showcasing potential neuroprotective and symptomatic benefits. The company serves a global clientele, targeting markets in North America and Europe, where it collaborates with healthcare providers, research institutions, and patient advocacy groups to reach both doctors and patients directly impacted by these conditions.

Prilenia Therapeutics generates revenue primarily through partnerships and collaborations within the healthcare sector, focusing on the development and commercialization of its therapies. The structure of their transactions typically involves agreements with pharmaceutical companies for the co-development and potential distribution of their products, including Pridopidine. Their revenue model may include milestone payments associated with clinical trial achievements and royalties from future sales of their therapies. While specific pricing plans remain undisclosed, the company's business strategy is geared toward establishing substantial relationships with healthcare providers and stakeholders that can facilitate the adoption of their products in the treatment of neurodegenerative diseases.

Prilenia Therapeutics is actively working on the development of new products to enhance their therapeutic offerings. Utilizing the recent funding of USD 10. 000 mn from the Series B round, the company plans to expand its reach into new markets in North America and Europe by 2025. The capital raised will support ongoing clinical trials and strategic partnerships to facilitate the launch of Pridopidine and other therapies.

The company has also secured venture funding from MaasInvest, which will aid in advancing its growth initiatives.